Arash Rezazadeh

2.6k total citations
58 papers, 809 citations indexed

About

Arash Rezazadeh is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Arash Rezazadeh has authored 58 papers receiving a total of 809 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Surgery, 25 papers in Oncology and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Arash Rezazadeh's work include Bladder and Urothelial Cancer Treatments (18 papers), Prostate Cancer Treatment and Research (15 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Arash Rezazadeh is often cited by papers focused on Bladder and Urothelial Cancer Treatments (18 papers), Prostate Cancer Treatment and Research (15 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Arash Rezazadeh collaborates with scholars based in United States, France and Italy. Arash Rezazadeh's co-authors include Roberto Bolli, Buddhadeb Dawn, Greg Hunt, Jai Varma, Adam Stein, Xian‐Liang Tang, Sumanth D. Prabhu, Jan Kajstura, Piero Anversa and Marcello Rota and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Arash Rezazadeh

49 papers receiving 793 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arash Rezazadeh United States 12 491 337 197 181 123 58 809
Joshua Kellner United States 13 276 0.6× 325 1.0× 439 2.2× 131 0.7× 30 0.2× 23 812
Kosuke Tsuboi Japan 9 253 0.5× 281 0.8× 368 1.9× 96 0.5× 59 0.5× 19 702
Kotaro R. Shibata Japan 14 295 0.6× 220 0.7× 198 1.0× 97 0.5× 75 0.6× 20 664
Jennifer Macko United States 12 379 0.8× 744 2.2× 76 0.4× 172 1.0× 128 1.0× 16 1.1k
Shailen R. Patel United States 10 515 1.0× 923 2.7× 101 0.5× 129 0.7× 251 2.0× 12 1.3k
Angelique A.M. van Oorschot Netherlands 7 347 0.7× 446 1.3× 235 1.2× 33 0.2× 113 0.9× 8 678
Zeeshan Pasha United States 14 498 1.0× 636 1.9× 512 2.6× 84 0.5× 133 1.1× 16 1.2k
Mitsugu Tanii Japan 10 258 0.5× 411 1.2× 76 0.4× 230 1.3× 49 0.4× 14 760
Matthews Chacko United States 7 264 0.5× 161 0.5× 245 1.2× 64 0.4× 152 1.2× 10 512
Alessandra Tritarelli Italy 13 206 0.4× 424 1.3× 141 0.7× 105 0.6× 160 1.3× 18 710

Countries citing papers authored by Arash Rezazadeh

Since Specialization
Citations

This map shows the geographic impact of Arash Rezazadeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arash Rezazadeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arash Rezazadeh more than expected).

Fields of papers citing papers by Arash Rezazadeh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arash Rezazadeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arash Rezazadeh. The network helps show where Arash Rezazadeh may publish in the future.

Co-authorship network of co-authors of Arash Rezazadeh

This figure shows the co-authorship network connecting the top 25 collaborators of Arash Rezazadeh. A scholar is included among the top collaborators of Arash Rezazadeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arash Rezazadeh. Arash Rezazadeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Benjamin, David J. & Arash Rezazadeh. (2025). Characterization of genitourinary drug approvals by the FDA, 2020-2024.. Journal of Clinical Oncology. 43(5_suppl). 872–872.
2.
Calais, Jérémie, Kim N., Johann S. de Bono, et al.. (2025). Efficacy of 177 Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis.. Journal of Clinical Oncology. 43(5_suppl). 121–121. 2 indexed citations
3.
Rezazadeh, Arash, et al.. (2025). Zebrafish as a model for assessing biocide toxicity: A comprehensive review. Toxicology Reports. 14. 101980–101980. 1 indexed citations
4.
Büsselberg, Dietrich, et al.. (2025). The effects of incretins as a double-edged sword on cancer. Molecular Biology Reports. 52(1). 965–965.
5.
Harada, Garrett K., Steven N. Seyedin, Armon Azizi, et al.. (2024). A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy. Advances in Radiation Oncology. 10(1). 101671–101671. 1 indexed citations
6.
Sadeghi, Sarmad, Nataliya Mar, Denice Tsao‐Wei, et al.. (2024). Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology. 42(16_suppl). 4577–4577.
7.
Mar, Nataliya, et al.. (2024). Diversity among editorial boards of genitourinary oncology journals.. Journal of Clinical Oncology. 42(4_suppl). 481–481.
8.
9.
Benjamin, David J. & Arash Rezazadeh. (2023). Characterization and survival benefit of drugs approved for metastatic prostate cancer.. Journal of Clinical Oncology. 41(6_suppl). 81–81. 1 indexed citations
10.
Rathmell, W. Kimryn, Geoffrey I. Shapiro, Jordi Rodón, et al.. (2023). A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.. Journal of Clinical Oncology. 41(16_suppl). 3104–3104. 2 indexed citations
11.
Soorki, Mehdi Naderi, et al.. (2023). Multi-Point Channel Charting for Long Range Wireless Networks: an Experimental Study. Aaltodoc (Aalto University). 399–405. 2 indexed citations
12.
Benjamin, David J. & Arash Rezazadeh. (2022). Quality of life in sexual minorities following prostate cancer treatment. Nature Reviews Urology. 19(6). 323–324. 2 indexed citations
13.
Loriot, Yohann, Arjun Vasant Balar, Daniel P. Petrylak, et al.. (2020). LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI). Annals of Oncology. 31. S1156–S1156. 19 indexed citations
14.
15.
Rocca, Renato V. La & Arash Rezazadeh. (2011). Carmustine-impregnated wafers and their impact in the management of high-grade glioma. Expert Opinion on Pharmacotherapy. 12(8). 1325–1332. 3 indexed citations
16.
Rezazadeh, Arash, et al.. (2009). The Role of Human Papilloma Virus in Lung Cancer: A Review of the Evidence. The American Journal of the Medical Sciences. 338(1). 64–67. 46 indexed citations
17.
Sanganalmath, Santosh K., Adam Stein, Yiru Guo, et al.. (2009). The beneficial effects of postinfarct cytokine combination therapy are sustained during long-term follow-up. Journal of Molecular and Cellular Cardiology. 47(4). 528–535. 8 indexed citations
18.
Flaherty, Michael P., Yiru Guo, Sumit Tiwari, et al.. (2008). The role of TNF-α receptors p55 and p75 in acute myocardial ischemia/reperfusion injury and late preconditioning. Journal of Molecular and Cellular Cardiology. 45(6). 735–741. 38 indexed citations
19.
Kloecker, Goetz, et al.. (2008). Brain Stem and Clivus Plasmacytoma. The American Journal of the Medical Sciences. 336(6). 503–503. 2 indexed citations
20.
Kantelhardt, Sven R., et al.. (2003). Recurrent Aortic Dissection in Marfan???s Syndrome: Possible Effects of Anticoagulation. Cardiology in Review. 11(4). 240–243. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joshua Kellner Breakdown of academic impact, for papers by Kosuke Tsuboi Breakdown of academic impact, for papers by Kotaro R. Shibata Breakdown of academic impact, for papers by Jennifer Macko Breakdown of academic impact, for papers by Shailen R. Patel Breakdown of academic impact, for papers by Angelique A.M. van Oorschot Breakdown of academic impact, for papers by Zeeshan Pasha Breakdown of academic impact, for papers by Mitsugu Tanii Breakdown of academic impact, for papers by Matthews Chacko Breakdown of academic impact, for papers by Alessandra Tritarelli
Rankless by CCL
2026